DIRECT COST ESTIMATION OF PSORIASIS TREATMENT IN TURKEY- RESULTS FROM A DELPHI PANEL
Author(s)
Atakan N1, Cavusoglu Sezen S2, Malhan S3, Oksuz E3, Yalcin B4
1Hacettepe University, Ankara, Turkey, 2Novartis, Istanbul, Turkey, 3Baskent University, Ankara, Turkey, 4Ankara Numune Training and Research Hospital, Ankara, Turkey
OBJECTIVES: The purpose of this study was to estimate the annual direct costs of psoriasis treatment from a public payer perspective (SSI) in Turkey. METHODS: Delphi panel was organized for collecting data based on clinicians’ experience. The type and number of resources used in treating psoriasis was determined by two experts. Follow up visits, hospital and emergency admissions, complications and side effects were included. Unit costs for each resource were determined with SSI perspective based on country-specific 2016 reimbursement price list. Costs associated with comorbidities, complications and side effects were calculated separately based on Delphi panel data and included in the total cost in accordance with their prevalence rates. RESULTS: According to the Delphi panel, Narrow-band ultraviolet B is an intervention performed for 40% of the patients while hydrotherapy is used in 30%, Psoralen Ultraviolet A is administered in 10% and surgical therapy is used in 1.6% of the patients. Conventional systemic treatments (methotrexate/cyclosporine) are used in 15% of the patients while biologic treatments are used in 1%. Among reimbursed biologic treatments, treatment cost for Adalimumab is €5,639.7 including drug monitoring cost, €8,145.3 for Infliximab, €5,422.1 for Etanercept and €8,186.0 for Ustekinumab. The mean annual cost per patient was €165 for outpatient visit, €838.0 for inpatient treatment, €308.1 for intervention and €315.1 for prescription/pharmaceutical costs. The cost of comorbid disease was €278.2 per patient annually. The mean cost of complications and side effects is €795.7 on an annual basis per patient. The mean annual total cost of psoriasis is €2,700.2 per patient. CONCLUSIONS: These results contribute to increase awareness on treatment patterns and associated costs of the disease in Turkey.
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PSS29
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Sensory System Disorders